

INFORME DE BÚSQUEDA Y SÍNTESIS DE COSTO-EFECTIVIDAD

Guía de Práctica Clínica Enfermedad Pulmonar Obstructiva Crónica 2019

EN PERSONAS CON ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA (EPOC) CON MÁS DE 1 EXACERBACIÓN AMBULATORIA U HOSPITALIZACIÓN POR EXACERBACIÓN EN AÑO PREVIO ¿SE DEBE REALIZAR CONTROL DE SEGUIMIENTO CADA 3 MESES EN COMPARACIÓN A REALIZAR CONTROL DE SEGUIMIENTO CADA 6 MESES?

Uno de los factores a considerar para formular una recomendación en Guías de Práctica Clínica con la metodología “*Grading of Recommendations Assessment, Development and Evaluation*” es la relación entre la efectividad y los costos de las intervenciones a evaluar.

BÚSQUEDA DE EVALUACIONES ECONÓMICAS

La búsqueda consideró estudios de costo-efectividad y revisiones sistemáticas de evaluaciones de costo-efectividad de si se debe realizar control de seguimiento cada 3 meses versus a realizar control de seguimiento cada 6 meses, en personas con enfermedad pulmonar obstructiva crónica (EPOC) con más de 1 exacerbación ambulatoria u hospitalización por exacerbación en año previo. Se identificaron términos MESH y términos de texto libre asociados a la población. La búsqueda consideró estudios publicados en inglés y español, en las siguientes bases de datos: MEDLINE, EMABASE, COCHRANE, GOOGLE, BRISA y en el National Institute for health and Care Excellence (NICE).

Ver detalle en Anexo 1 “*Términos de Búsqueda y Resultados de la búsqueda*”.

SÍNTESIS DE EVIDENCIA SEGÚN PREGUNTA

Una vez ejecutada la búsqueda, se evaluaron los títulos y resúmenes de los estudios encontrados y se seleccionaron las evaluaciones económicas que utilizaran como método la costó-utilidad y costo-efectividad.

La búsqueda entregó como resultado 67 artículos, los cuales fueron eliminados por título y abstract por no responder a la pregunta de investigación formulada para enfermedad pulmonar obstructiva crónica (EPOC).

ANEXO 1: ESTRATEGIA DE BÚSQUEDA Y RESULTADOS DE LA BÚSQUEDA

| | Términos libres | DECS | MeSH |
|---|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| P | Personas con enfermedad pulmonar obstructiva crónica (EPOC) estable (con 0 o 1 exacerbación ambulatoria en el año previo) | Pulmonary Disease, Chronic Obstructive OR (Airflow Obstruction, Chronic Airflow Obstructions, COAD COPD Chronic Airflow Obstruction Chronic Airflow Obstructions Chronic Obstructive Airway Disease Chronic Obstructive Lung Disease Chronic Obstructive Pulmonary Disease) | "pulmonary disease, chronic obstructive"[MeSH Terms] |
| I | control de seguimiento cada 3 meses | | |
| C | control de seguimiento cada 6 meses | | |
| O | Cost, economic, cost-effective, cost-effectiveness, cost-benefit, health outcome, health technology assessment | Cost-Benefit Analysis | "Cost-Benefit Analysis"[Mesh] |

| Base de datos | Fecha de búsqueda | Resultados | Resultados después de remover duplicados |
|-----------------------------------|-------------------|------------|------------------------------------------|
| Medline-Pubmed | 02-10-2019 | 2 | 2 |
| EMBASE | 02-10-2019 | 4 | 4 |
| NICE | 02-10-2019 | 36 | 36 |
| BRISA (RedETSA) | 03-10-2019 | 12 | 12 |
| COCHRANE | 25-09-2019 | 5 | 5 |
| Google scholar | 25-09-2019 | 8 | 8 |
| Eliminados por título y resúmenes | | | 67 |
| Total, lectura texto completo | | | 0 |
| Total | | | 0 |

ESTRATEGIAS DE BÚSQUEDA

PUBMED:

| Estrategia | |
|------------|-----------------------------------------------------------------------------------------------------------------------------------|
| #6 | Search (chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*) |
| #7 | Search emphysema* OR "obstructive lung disease" |
| #8 | Search chronic* AND airflow* AND (obstruction* OR limitation*) |
| #9 | Search (hypercapni* AND respiratory* AND failure*) |
| #10 | Search aecopd |
| #11 | Search #6 OR #7 OR #8 OR #9 OR #10 |
| #18 | Search (cost* effective*[tiab] OR cost* utilit*[tiab] OR cost* benefit*[tiab] OR cost* minimis*[tiab] OR cost* consequenc*[tiab]) |
| #19 | Search cost-benefit analysis [mh] |
| #26 | Search ("follow-up" or followup or "follow up") |
| #27 | Search (strateg* or visit*) |
| #28 | Search #11 AND #26 AND #27 |
| #29 | Search #18 OR #19 |
| #33 | Search (#19 OR #18) AND #28 |

EMBASE:

| Estrategia | |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | (chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] |
| 2 | (emphysema* or "obstructive lung disease").mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] |
| 3 | (chronic* and airflow* and (obstruction* or limitation*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] |
| 4 | (hypercapni* and respiratory* and failure*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] |
| 5 | chronic obstructive lung disease/ or aecopd.mp. |

| | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6 | 1 or 2 or 3 or 4 or 5 |
| 7 | ("cost-effectiveness" or "cost effectiveness" or "cost-utility" or "cost utility" or cost minimi\$).ti,ab. |
| 8 | ("follow-up" or followup or "follow up").mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] |
| 9 | (strateg* or visit*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] |
| 10 | 6 and 8 and 9 |
| 11 | 7 and 10 |
| 12 | ((("6" or six) and month).ab,ti. |
| 13 | 11 AND 12 |

NICE

| |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <u>Estrategia</u> |
| (chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*) AND ("follow-up" OR followup OR "follow up") AND (Cost-effectiveness) AND (((("6" or six) and month)) |

BRISA:

| |
|-----------------------------------------|
| Estrategia |
| enfermedad pulmonar obstructiva crónica |

COCHRANE

| ID | Search |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #1 | (cost-effectiveness or "cost effectiveness" or cos-utility analysis or "cost-utility analysis" or cost-benefit analysis or "cost-benefit analysis" or "cost effectiveness analysis") |
| #2 | (chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*):ti,ab,kw |
| #3 | emphysema* OR "obstructive lung disease" |
| #4 | chronic* AND airflow* AND (obstruction* OR limitation*) |
| #5 | (hypercapni* AND respiratory* AND failure*) |
| #6 | aecopd |
| #7 | #2 OR #3 OR #4 OR #5 |
| #8 | ("follow-up" or followup or "follow up") |
| #9 | (strateg* or visit*) |
| #10 | ((("6" or six) and month):ab AND (year OR "12" OR annual):ab |
| #11 | #8 AND #9 |

| | |
|-----|---------------------------------------------------------------------------|
| #12 | (cost\$ near/2 (effective\$ or utilit\$ or benefit\$ or minimis\$)):ti,ab |
| #13 | #1 AND #12 |
| #14 | #11 AND #13 AND #7 |
| #15 | #10 AND #14 |

Google Scholar

| ID | Search |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #1 | (cost-effectiveness OR "cost effectiveness" OR "economic evaluation") AND (severe chronic obstructive pulmonary disease) AND (("follow-up" OR followup OR "follow up")) AND (("6" or six) and month) |